Literature DB >> 1425926

Selective and differential binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans.

L Ramsden1, C C Rider.   

Abstract

The binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to acidic polysaccharides was investigated by affinity chromatography of the recombinant, radioiodinated interleukins on columns of immobilized polysaccharide. Each interleukin showed selective binding retention. Overall heparin bound all four interleukins significantly, whereas chondroitin sulfate provided little retention. IL-1 alpha and IL-1 beta showed differential binding, with only the latter binding to hyaluronic acid. IL-2 was virtually completely retained on fucoidan. Noniodinated recombinant IL-2 bound similarly to fucoidan, and fucoidan was found to sequester IL-2 activity in a bioassay employing IL-2-dependent CTLL cells. In all other cases tested, interleukin retention was partial, implying that interleukin binding sites are sparsely distributed along the polysaccharide chains. These findings suggest that during the immune response, interleukins will tend to be retained at sites of secretion by interaction with glycosaminoglycans in the extracellular matrix and on cell surfaces.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425926     DOI: 10.1002/eji.1830221139

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis.

Authors:  B Eckes; D Kessler; M Aumailley; T Krieg
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

Authors:  Sean Gill; Thomas N Wight; Charles W Frevert
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

3.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.

Authors:  Sven Létourneau; Ester M M van Leeuwen; Carsten Krieg; Chris Martin; Giuseppe Pantaleo; Jonathan Sprent; Charles D Surh; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

Review 4.  Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection.

Authors:  Inkyung Kang; Mary Y Chang; Thomas N Wight; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

5.  Structural study of fucoidan from Cladosiphon okamuranus TOKIDA.

Authors:  M Nagaoka; H Shibata; I Kimura-Takagi; S Hashimoto; K Kimura; T Makino; R Aiyama; S Ueyama; T Yokokura
Journal:  Glycoconj J       Date:  1999-01       Impact factor: 2.916

6.  Transforming growth factor beta 1-hyaluronic acid interaction.

Authors:  P Locci; L Marinucci; C Lilli; D Martinese; E Becchetti
Journal:  Cell Tissue Res       Date:  1995-08       Impact factor: 5.249

7.  Heparin inhibits IFN-gamma-induced fractalkine/CX3CL1 expression in human endothelial cells.

Authors:  Masaharu Hatakeyama; Tadaatsu Imaizumi; Wakako Tamo; Koji Yamashita; Hidemi Yoshida; Ikuo Fukuda; Kei Satoh
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

8.  Biological effects of fucoidan isolated from Fucus vesiculosus on thrombosis and vascular cells.

Authors:  Kyu-Won Kwak; Kil-Sang Cho; Ok-Jin Hahn; Kwang-Hyung Lee; Boo-Yong Lee; Jung-Jae Ko; Kwang-Hoe Chung
Journal:  Korean J Hematol       Date:  2010-03-31

9.  Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin.

Authors:  Ryan Serra; Abdel-Ghany Al-Saidi; Nikola Angelov; Salvador Nares
Journal:  J Inflamm (Lond)       Date:  2010-09-15       Impact factor: 4.981

10.  Altered endochondral ossification in collagen X mouse models leads to impaired immune responses.

Authors:  E Sweeney; M Campbell; K Watkins; C A Hunter; O Jacenko
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.